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Abstract
The immunomodulatory indoleamine 2,3-dioxygenase, a key enzyme of the tryp-
tophan catabolism, is strongly connected to tumoural immune tolerance due to
overexpression in certain tumours. Local depletion of the essential amino acid
and the accumulation of cytotoxic tryptophan-derived metabolites induce an ar-
rest of T-cell proliferation and suppress the immune response. This immune es-
caping state prevents an efficient immunotherapy as well.
Natural just as synthetic compounds have been identified and developed for the
novel drug target. Until now, only two of them have been assayed on tumour
cells: 1-Methyl-tryptophan and Methyl-thiohydantoin-tryptophan. Both revea-
led, administered in combination with paclitaxel, a significant tumour regression.
With the intent to develop novel small-molecule IDO inhibitors, we synthesized
new derivatives based on Methyl-thiohydantoin-tryptophan scaffold. However,
subsequently performed enzyme assay on human IDO displayed minor inhibitor
activity as the parent substance.
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Chapter 1
Introduction
1.1 What is IDO?
Indoleamine 2,3-dioxygenase (IDO) is one of the key enzymes of a branched en-
zymatic cascade, known as the kynurenine pathway (KP). The KP is the prin-
cipal catabolic route for the essential amino acid L-tryptophan (L-trp) in mam-
mals which is not required for protein biosynthesis. Although L-trp is the ra-
rest of all amino acids, several biologically active compounds originate from it,
among them the aminergic neurotransmitter serotonine (5-hydroxytryptamine,
5-HT) and the neurohormone melatonine.
The initial reaction of the KP involves the oxidative cleavage of L-tryptophan
into N-formylkynurenine.1 Two different but isofunctional, heme-containing en-
zymes catalyse this rate-determining degradation process: tryptophan 2,3-dioxy-
genase (TDO) and indoleamine 2,3-dioxygenase (IDO). N-formylkynurenine is
then promptly hydrolysed to L-kynurenine and subsequently degraded to a se-
ries of partly neuroactive metabolites including 3-hydroxykynurenine, quinolinic
acid, kynurenic acid and nicotineamide adeninedinucleotide (NAD).
Unlike TDO, which is found only in the liver, IDO is distributed in a huge number
of human tissues, such as brain, lung, small intestine and placenta.2 Whereas
TDO converts only L-trp, IDO evinces a very widespread substrate specifity for
various indoleamines. Ball and coworkers 3,4 have recently characterised a novel
enzymatic isoform of IDO and termed it indoleamine 2,3-dioxygenase-2 (IDO-2).
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1.2 Physiological functions
As an intracellular enzyme, IDO can be induced by several inflammatory stimuli,
e.g. cytokines (IL-1, TNF). Its pivotal inducer in vitro and in vivo is interferon-γ
(IFN-γ).5 This is the reason why IDO has been assumed to be part of the innate
immune system. However, its performance is not always in favour of the host.
1.2.1 Host defence
Increased IDO activity is reflected in local depletion of free serum L-trp and the
accumulation of tryptophan-derived kynurenine pathway metabolites.
Some microorganisms (auxotrophs) cannot synthesize their own tryptophan. They
depend on an external source and react very sensitively to the enhanced IDO ac-
tivity. Furthermore, IDO is induced by bacterial lipopolysaccharide (LPS) and
other endotoxines. IDO expression inhibits several pathogenic agents like bacte-
ria (Chlamydia pneumoniae, Toxoplasma gondii) and viruses (Cytomegalo virus, Herpes
simplex virus) from growing and replicating.5
Nevertheless, its infection-controlling role has become more and more nested to
reconcile with its immunomodulating effect.
1.2.2 Immune supervisor
Immunomodulators affect the immune system for a balanced response: immu-
nosuppression is justified and imperative at autoimmune diseases, organ trans-
plantation, or immune-mediated abortion. Inappropriate suppression, however,
causes uncontrolled infections and tumour growth.
Landmark work by Munn and colleagues 6 evinced that, during murine pregnacy,
IDO expressing cells protects the allogenic fetus. IDO inhibition lets the maternal
T-cells to instigate fetal rejection. Therefore, (interferon-γ-mediated) IDO, when
expressed in antigen presenting cells (APC) like macrophages and dendritic cells
(DC), plays a crucial role in adaptive T-cell immune responses.7 In a similar man-
ner to its antimicrobial effect, IDO is starving T-cells of tryptophan. These are
extremely sensitive to the lack of the essential amino acid, leading to an arrest
of their cell cycle and subsequently to apoptosis.8 Moreover, certain downstream
tryptophan catabolites suppress T-cell proliferation in order to facilitate immune
tolerance.9
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1.3 Pathophysiological part
Enhanced IDO activity and the production of high levels of kynurenines correlate
with several immunological diseases, which affect the central nervous system, as
well as inflammatory diseases. However, for the last decades, research has been
focused on the connection between IDO and tumours, especially due to the fact
that IDO is involved in tumour-induced tolerance. Tumours are capable to escape
from immune surveillance evolving a pathological condition of tolerance against
their own antigens. 10,11
The role of IDO is not clear yet: First, elevated IDO activity in cancer patients
was inferred with IFN-γ exposure to have an antitumoural effect by depletion
of tryptophan and production of toxic kynurenines. However, tumour cells are
highly pliable: They are able to reverse the IDO immune suppressive activity
in favour of their own profit and to establish a rampart towards the immune
response. Not only does this pathological state render possible that tumour grow
undisturbed, but it also makes difficult for clinical immunotherapy difficult to
succeed.
Muller and coworkers 12 explained one way of IDO becoming deregulated in
cancer cells, which involves the tumour suppression gene Bin1. Bin1, which is
decreased in several cancer types, controls the expression of the Indo gene. The
Indo gene encodes the IDO enzyme. Mouse knockout studies demonstrate that a
lack of Bin1 augments the expression of IDO.
Therefore, IDO illustrates an interesting and important novel target for cancer
drug development.
1.4 Medicinal Chemistry of IDO inhibitors
Introduction
The development of IDO-inhibitors has been focused, so far, on the natural sub-
strate L-Tryptophan. Competitive as well as non-competitive inhibitors have
been identified endowed with potency in the high micromolar range. Recent re-
views summarize the variety of compounds that have been discovered to possess
IDO inhibitor activities. 13,14,15
However, reported pharmacological data must be interpreted cautiously: Two
enzymatic isoforms of IDO – IDO-1 and IDO-2 3,4 – exist and different IDO sources
(human, murine or recombinant) are in use. Austin and coworkers 16 recently re-
ported that the competitive inhibitor 1-Methyl-L-tryptophan is a better inhibitor
for recombinant mouse IDO (Ki = 105 µM) than for recombinant human IDO (Ki
= 62 µM).
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1.4.1 Competitive inhibitors
Tryptophan Analogues
The amino acid substrate L-trp (1, figure 1.1) has earlier been found to be endo-
wed with inhibitory activity at high concentrations (> 0.2 mM). 17,18 Therefore,
most known competitive IDO inhibitors are tryptophan analogues.
Figure 1.1
The following modifications have been performed on the tryptophan scaffold
1. Indole modifications
Tryptophan analogues with substitution of the indolic nitrogen with a me-
thyl group (1-Methyl-tryptophan, 1-MT, 2, figure 1.2) or replacing it with a
sulphur atom (benzothiazole derivative, 3) or an oxygen atom (benzofuran
derivative, 4) led to inhibitors with Ki ranging from low to high micromolar
concentration. 19
Thus, 1-MT, a commercially available compound, is the prototype of this
class of inhibitors and possesses a Ki about 30 µM. 20 Several studies repor-
ted the docking process to the active site of IDO to be stereoselective. Thus,
(S)-1-MT was more potent than its (R)-antipode. (63% and 12% of inhibition
at 100 µM, respectively). 20 All of them, lacking the acidic proton at the N-1
position of Trp, may prevent the first step of the enzymatic oxidation.
4
Figure 1.2
2. Substitutions at the phenyl ring
Substitutions with electron-withdrawing groups on the phenyl ring of Trp
at C-5, C-6, and C-7 positions lead to active compounds whereas the pre-
sence of electron-releasing group speeds up the IDO oxidation. Indeed, 5-
Bromo (5, figure 1.3, 56% inhibition at 1mM), 6-Fluoro (6, 54% inhibition at
1mM), 6-Nitro (7, 52% inhibition at 1mM, Ki = 180 µM for (S)-enantiomer),
7-Fluoro (8, Ki = 37 µM) as well as 4,7-Difluoro (9, Ki = 40 µM) and 5,7-
Difluoro (10, Ki = 24 µM) resulted in the most active inhibitors. 21,22
However, many members of this class of compounds act as substrates as
well and thus they undergo IDO oxidation, at least in part.
Figure 1.3
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3. Side chain modifications
Only few modifications are tolerated on the distal aminoacidic moiety: it
can be methylated or esterified but the amino group could not be remo-
ved. Recently potent inhibitors were discovered in which the aminoaci-
dic moiety has been cyclized to form a thiohydantoine ring. Compound
Methyl-thiohydantoin-tryptophan (MTH, 11, figure 1.4), reported as a ne-
croptosis inhibitor as well (“Necrostatin-1” 23), displayed a Ki of 11.4 µM,
being a potent IDO inhibitor. 12
Sulfur containing inhibitors
Various dithiocarbamate derivatives have been reported to present IDO inhibi-
tory activity. By screening of commercially available indole derivatives, Gas-
pari and coworkers 24 discovered the natural product brassinin (12, figure 1.4)
to display a moderate competitive IDO inhibitory activity with a Ki about 98 µM.
Further structure activity relationship (SAR) studies at synthetic brassinin deri-
vatives showed that the dithiocarbamate side chain is crucial for the inhibitory
activity. Most likely this moiety binds to the heme iron acting as chelating agent.
Moreover, the indole ring is not necessary in this class of compounds and the dis-
tal thiomethyl group could be substituted with more hindered aromatic groups.
Figure 1.4
A new lead compound
Yue and coworkers 25 have recently identified a novel non-indolic-based lead
structure for competitive IDO inhibitors: 4-amino-1,2,5-oxadiazole-3-carboximidamide
(13, figure 1.5). Further SAR studies showed the phenyl derivatives to be the most
potent ones.
6
Figure 1.5
1.4.2 Non-competitive inhibitors
1. β-carboline derivatives
About two decades ago, a series of β-carboline derivatives was reported to
act as IDO inhibitors, among them, norharman as the most active one.26
They show non-competitive inhibition behavior.27 Modifications at the β-
carboline structure have been performed on the pyridine and phenyl rings
evidencing that large alkyl chain in the C-3 position of the β-carboline scaf-
fold lead to potent inhibitors; i.e.: 3-butyl-β-carboline (14, figure 1.6) pos-
sesses an IDO inhibition Ki about 3 µM. 28
The natural product brassilexin(15, Ki about 5 µM) and 4-phenylimidazole
(16) are other compounds of this class, reported as potent non-competitive
IDO inhibitors. 27,28
Figure 1.6
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2. Various structures
The screening of a library of marine invertebrates extracts unveiled the new
polyketide annulin C (17, figure 1.7) and the known compounds annulin
A and annulin B, which are natural products isolated from the marine hy-
droid Garveia annulata, to act as submicromolar inhibitors of IDO.29 Another
compound, found by the same screening program, was exiguamine A (18),
a novel alkaloid of the marine sponge Neopetrosia exigua. It displayed a Ki
of 120 nM.30
Kumar and coworkers 31 supposed the naphthoquinone core of the annu-
lins as the key pharmacophore. Thus, led them to identify a series of naph-
thoquinone derivatives, which showed potent inhibitory activity. Among
them, three pyrano-naphthoquinone-based compounds were reported to be
the most potent IDO inhibitors so far (19, Ki = 61–70 nM).
Yeast target-based screening disclosed another potent non-indolic IDO inhi-
bitor. Thus, the N-methyl-N’-9-phenanthrenyl-imidodicarbonimic diamide
(20) was reported to possess a Ki of 1.5 µM against recombinant human
IDO. 32
Figure 1.7
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1.4.3 Therapeutical use of IDO inhibitors
Since elevated IDO activity is linked to tumoural immune tolerance and immu-
nosuppression, it has become a crucial new drug target. Muller and colleagues 12
demonstrate the antitumoural effect of IDO inhibitors (1-MT, MTH) on a mouse
model of breast cancer. 1-MT and MTH, by themselves, only slowed but were not
able to arrest tumour growing. Combining 1-MT with common chemotherapeu-
tical drugs, which are used for breast cancer treatment, lead to significant results.
1-MT with paclitaxel, a taxane, caused an average of 30% in tumour volume re-
gression as well as combining MTH with paclitaxel; whereas paclitaxel treatment
by itself only inhibited tumour growth. Significant tumour decrease was achie-
ved even combining 1-MT with cisplatin, cyclophosphamide and doxorubicin.
1-MT is a rather weak IDO inhibitor with poor enzyme selectivity: However, it is
one of few inhibitors that has been assayed in vivo, so far.
9
Chapter 2
Research tasks
2.1 Scope
Muller and coworkers 12 discovered, by screening commercially available indo-
leamines, a competitive IDO inhibitor that displayed a threefold inhibitor activity
and much better enzyme selectivity related to 1-MT in cell-based assays. Phar-
macological experiments with Methyl-thiohydantoin-tryptophan revealed simi-
lar oral bioavailability and in combination with paclitaxel similar tumour regres-
sion as 1-MT in vivo.
Natural as well as synthetic compounds were characterised as more potent IDO
inhibitors than 1-MT. However, 1-MT and MTH are, so far, the only two compe-
titive inhibitors assayed on tumour tissue in vivo.
Cancer immunotherapeutic strategies have focused mainly on immune system’s
stimulation. Biological agents, such as cytokines, which are currently the main
immunotherapeutics, acitivate and amplify immune response towards tumour
antigens. However, in the last decade, targeted therapies with small molecules
become rampant - even due to the fact that small molecules have further ad-
vantages compared to biological agents, including production, application and
immunogenicity. 33
Based on these facts and, additionally, that no derivatives of MTH ever appeared
in context with IDO inhibition or cancer treatment, we targeted to develop novel
small-molecule IDO inhibitors: We designed and synthesized new derivatives
starting from Methyl-thiohydantoin-tryptophan scaffold, suitable for pharmaco-
logical studies.
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2.2 Synthesis of 5-(1H-indol-3ylmethyl)-2-thio-
hydantoin derivatives
2-Thiohydantoin derivatives 22 – 26 have been synthesized starting from the ap-
propriate Tryptophan methyl ester hydrochloride (21) according to the known
procedure.23 Thus, as displayed in Scheme 1, by treating 21 with the appropriate
alkyl isothiocyanate in the presence of triethylamine in dichloromethane (DCM),
the corresponding 5-(1H-indol-3ylmethyl)-2-thiohydantoin derivatives 22 – 26
were obtained in high yields.
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2.3 Synthesis of 5-(5-Fluoro-1H-indol-3ylmethyl)-
3-methyl-2-thiohydantoin
5-Fluoro-Necrostatin (29) has been obtained starting from 5-Fluoro-tryptophan
(27), according to Scheme 2. Thus, derivative 27 has been transformed in the
corresponding methyl ester 28 through the reaction with thionyl chloride in dry
methanol solution. Compound 28 was treated without further purification with
methylisothiocyanate as reported above to afford the corresponding 5-(5-Fluoro-
1H-indol-3ylmethyl)-3-methyl-2-thiohydantoin (29), in 37% yield.
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2.4 Synthesis of 5-(1-N-Methyl-1H-indol-3ylmethyl)-
3-methyl-2-thiohydantoin
1-Methyl-Necrostatin (32) has been prepared in two steps as figured in Scheme 3.
Briefly, 1-N-Methyl-tryptophan methyl ester (31) has been obtained in 75% yield,
by reacting at room temperature commercially available 1-Methyl-tryptophan
(30) with thionyl chloride in dry methanol solution. The latter intermediate 31
was treated without further purification with methylisothiocyanate as reported
above to afford the corresponding 5-(1-N-Methyl-1H-indol-3ylmethyl)-3-methyl-
2-thiohydantoin (32), in 73% yield.
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2.5 Synthesis of 5-(1H-Indol-3-ylmethyl)-3-methyl-
hydantoin (O-Necrostatin-1)
O-Necrostatin-1 (34) has been synthesized as reported in scheme 4. 21was treated
with methylamine in methanol (4 d) to provide Tryptophan methyl amide (33) in
98% yield. It worked treating 21 with methylamine in ethanol (16 h) as well, ob-
taining Tryptophan methyl amid in 94% yield. The intermediate 33 was arranged
with triphosgene in the presence of triethylamine in dry dichloromethane to give
5-(1H-Indol-3-ylmethyl)-3-methyl-hydantoin (34). The reaction failed when ar-
ranging 33 with triphosgene in the presence of pyridine in dry dichloromethane.
14
2.6 Chiral HPLC
IDO inhibitor activity is related to stereospecifity. Peterson and colleagues 20 sho-
wed that (S)-MT is a more potent inhibitor than (R)-MT. Starting from these pre-
mises, we wanted to determine if IDO inhibitor activity differentiates between the
two stereoisomers of MTH as well. The compounds 25 and 26 have been submit-
ted to a chiral HPLC analysis proving their enantiomeric purity. Unfortunately,
as shown in the chromatogram in 2.1, the two reaction products are racemic. Ra-
cemisation might occur through the basic reaction conditions.
Figure 2.1
2.7 Enzyme activity
All synthesis products were evaluated by the pharmacological research group
of Prof. Moroni at the University of Florence, as novel competitive inhibitors of
human indoleamine 2,3-dioxygenase, extracted from placenta. The inhibition ac-
tivity was determined by measuring the amount of kynurine product (HPLC),
after incubating the purified enzyme with a constant quantity of L-tryptophan
(30 µM) in presence of the IDO inhibitor (100 µM). As reported in table 2.1, the
percentage of inhibition for 1-MT and MTH (reference compounds) was 45% and
35% respectively.
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compound R1 R2 R3 X inhibition % at 100 µMa
1-MT 2 45
MTH 11 H H Me S 35
22 H H n-Pr S 30
23 H H Bn S 16
24 H H Ph S 12
29 F H Me S 32
32 H Me Me S 21
34 H H Me O not active
a percentage of inhibition obtained by comparison of the amount of kynurenine
produced in the presence of L-tryptophan (30 µM) and IDO inhibitor (100 µM)
Table 2.1: Inhibition assay for the synthesized hydantoin derivatives
Unfortunatly, our synthetic compounds displayed lower inhibition potency and
solubility as their parent substance. Difficulty in reproducibility of the inhibition
assay have emerged as well.
However, indoleamine 2,3-dioxygenase is still an interesting drug target, preci-
sely because its crystal structure has been recently reported.34 Computer-guided
design will might lead to efficient inhibitors alternatives and they might support
a successful cancer treatment.
16
Chapter 3
Experimental section
3.1 General procedures
3.1.1 Chemistry
All the necessary reagents were purchased from Sigma Aldrich and used as recei-
ved. All syntheses were prepared under an inert argon or nitrogen atmosphere.
Precoated TLC plates with silica gel 60 F-254 (Merck) were used for thin layer
chromatography. Spots were visualized by UV lamp (254 nm) or by staining and
warming with phosphomolybdate (5% in EtOH) or permanganate reagent. Flash
column chromatography was performed using Merck silica gel 60 (0.040 – 0.063
mm) and on Biotage SP1 apparatus. Melting points were determined with a Bü-
chi 535 electrothermal apparatus (capillary method) and are reported uncorrec-
ted. 1H-NMR and 13C-NMR spectra were obtained with a Bruker AC 200 and
400 MHz spectrometer, and the chemical shifts are reported in parts per million
(ppm). The abbreviations used are as follows: s, singlet; d, doublet; dd, double of
a doublet; t, triplet; dt, double of a triplet; m, multiplet; b, broad; p, pseudo.
The chiral analysis of compounds 25 and 26 were performed on chiral HPLC
(CHIRALPAK® IB a stationary phase consisted of tris(3,5-dimethylphenylcarba-
mate) derivatized cellulose and immobilized on silica 5 µm). The chromatogram
was recorded with a PDA detector (set on from 190 to 350 nm), visualizing the
absorption in mAU on the optimized wavelength of absorbance (220 nm, 254
nm). The most effective mobile phase for resolution and enantioselectivity was a
mixture of n-hexane / i-propanol (85:15).
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3.1.2 Pharmacology
Tissue preparation
Placental human IDO was purified as reported in literature 2 with some modi-
fication. Briefly, the placenta were cut in pieces and washed with physiological
solution of 0.9% NaCl. The tissues were homogenized with 3 vol. of potassium
phosphate buffer 50 mM (pH 6.5), 1M EDTA and 1M DTT. After centrifugation at
14000 rpm for 30 min, the clear solution was poured into an ion exchange column
(Sephaldex S-100).
Enzymatic inhibition assay
The evaluation of IDO activity was conducted as reported in literature.35 Brie-
fly, the reaction mixture consisted of 20 µL of cytosol preparation and 80 µL of
phosphate buffer (pH 6.5), containing 10 mM ascorbate, 50 µM methylene blue,
200 µg catalase, and 30 µM L-tryptophan (the inhibitor is included within the 80
µL). The resulted mixture was incubated for 2h at 37◦C. By the addition of 100 µL
of 20% (w/v) trichloroacetic acid the reaction was terminated. The mixture was
centrifuged at 14000 rpm for 5 min. An aliquot of the supernatant was assayed
by HPLC to evaluate the amount of kynurenine product. Kynurenine was deter-
mined by HPLC, using a reverse-phase column (Sperisorb S5 ODS2, 10 cm) and
a mobile phase of 1 M ammonium acetate, 0.1 M acetic acid and 2% acetonitrile,
and an ultraviolet detector (Perkin Elmer model LC 90, 365 nm).
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3.2 Preparations
3.2.1 5-(1H-Indol-3-ylmethyl)-3-propyl-2-thiohydantoin (22)
Propylisothiocyanate (0.07 mL, 0.68 mmol) and triethylamine (0.18 mL, 1.30 mmol)
were added to a solution of L-Tryptophan methyl ester hydrochloride (0.15 g,
0.59 mmol) in dry DCM (15 mL) under argon. The resulting mixture was stir-
red at room temperature for 30 h. It was taken up with DCM (about 10 mL) and
evaporated under reduced pressure. The reaction mixture was purified by flash
chromatography, eluting with DCM / EtOAC (from 3 up to 30% of EtOAc) to
give derivative 22.
Yield: 0.13 g (77%) of a yellow solid, mp 123-124◦C
1H-NMR (DMSO, 400 MHz, Appendix: figure 5.1 – 5.3) δ 0.44 (t, J = 7.5 Hz, 3H),
1.09 (dq, J = 7.3 and 2.1 Hz), 3.16 (dq, J = 14.98 and 4.6 Hz, 2H), 3.35 (m, 2H under
H2O), 4.53 (pt, 1H), 6.95 (dt, J = 7.4 and 0.9 Hz, 1H), 7.03 (dt, J = 7.5 and 1.1 Hz,
1H), 7.06 (d, J = 2.4 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 10,32
(s, 1H), 10.88 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.4 – 5.5) δ 13.00, 22.55, 28.33, 43.73, 61.79,
109.38, 113.56, 120.75, 120.95, 123.30, 126.63, 129.69, 138.26, 176.95, 185.14.
3.2.2 5-(1H-Indol-3-ylmethyl)-3-benzyl-2-thiohydantoin (23)
Benzylisothiocyanate (0.86 mL, 0.65 mmol) and triethylamine (0.181 mL, 1.30
mmol) were added to a solution of L-Tryptophan methyl ester hydrochloride
(0.15 g, 0.59 mmol) in dry DCM (15 mL) under argon. The resulting mixture was
stirred at room temperature for 24 h. It was taken up with DCM (about 10 mL)
and evaporated under reduced pressure. The reaction mixture was purified by
flash chromatography, eluting with DCM / EtOAc (from 3 up to 30% of EtOAc)
to give derivative 23.
Yield: 0.08 g (41%) of a yellow solid, mp 182-183◦C.
1H-NMR (DMSO, 400 MHz, figure 5.6 – 5.7) δ 3.21 (dq, J = 23.6 and 4.4 Hz, 2H),
4.68 (m, 3H), 6.56 (d, J = 7.4 Hz, 2H), 6.95 (dt, J = 7.2 and 0.9 Hz, 1H), 7.00 – 7.09
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(m, 5H), 7.36 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 10,54 (s, 1H), 10.93 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.8 – 5.9) δ 28.01, 45.41, 62.27, 109.40, 113.67,
120.94, 121.06, 123.38, 126.78, 128.61, 129.03, 129.77, 130.44, 138.29, 176.77, 184.86.
3.2.3 5-(1H-Indol-3-ylmethyl)-3-phenyl-2-thiohydantoin (24)
Phenylisothiocyanate (0.12 mL, 0.65 mmol) and triethylamine (1.81 ml, 1.30 mmol)
were added to a solution of L-Tryptophan methyl ester hydrochloride (0.15 g,
0.59 mmol) in dry DCM (15 mL) under argon. The resulting mixture was stir-
red at room temperature for 4 h. It was taken up with DCM (about 10 mL) and
evaporated under reduced pressure. The reaction mixture was purified by flash
chromatography, eluting with DCM / EtOAc (from 0 up to 40% of EtOAc) to give
derivative 24.
Yield: 0.12 g (63%) of a yellow solid, mp 180◦C.
1H-NMR (DMSO, 400 MHz, figure 5.10 – 5.11) δ 3.33 (m, 2H under H2O), 4.71 (t,
J = 4.4 Hz, 1H), 6.63 – 6.65 (m, 2H), 6.96 (dt, J = 7.3 and 0.9 Hz, 1H), 7.07 (dt, J =
7.3 and 0.5 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 7.27 – 7.31 (m, 3H), 7.35 (d, J = 8.1 Hz,
1H), 7.55 (d, J = 7.9, 1H), 10,54 (s, 1H), 10.96 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.12 – 5.13) δ 28.81, 62.47, 109.29, 113.69,
120.88, 121.07, 123.39, 126.94, 129.67, 130.84, 130.91, 135.67, 138.29, 176.56, 184.88.
3.2.4 (S)-5-(1H-Indol-3-ylmethyl)-3-methyl-2-thiohydantoin (25)
Methylisothiocyanate (0.047 g, 0.65 mmol) and triethylamine (0.18 mL, 1.3 mmol)
were added to a solution of L-Tryptophan methyl ester hydrochloride (0.15 g,
0.59 mmol) in dry DCM (15 mL) under argon. The resulting mixture was stir-
red at room temperature for 24 h. It was taken up with DCM (about 10 mL) and
evaporated under reduced pressure. The reaction mixture was purified by flash
chromatography, eluting only with DCM to give derivative 25.
Yield: 0.096 g (63%) of a yellow solid, mp 152-154◦C.
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1H-NMR (DMSO, 400 MHz, figure 5.14 – 5.15) δ 2.85 (s, 3H), 3.14 (d, J = 5.0 Hz,
2H), 4.55 (t, J = 5.0 Hz, 1H), 6.95 (t, J = 7.4 Hz, 1H), 7.01 – 7.07 (m, 2H), 7.30 (d, J =
8.0 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H), 10,33 (s,1H), 10.88 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.16 – 5.17) δ 28.43, 29.08, 62.07, 109.80,
113.72, 120.83, 123.36, 126.46, 129.67, 138.26, 177.01, 185.27.
3.2.5 (R)-5-(1H-Indol-3-ylmethyl)-3-methyl-2-thiohydantoin (26)
Methylisothiocyanate (0.047 g, 0.65 mmol) and triethylamine (0.18 mL, 1.3 mmol)
were added to a solution of D-Tryptophan methyl ester hydrochloride (0.15 g,
0.59 mmol) in dry DCM (15 mL) under argon. The resulting mixture was stirred
at room temperature for 24 h under argon. It was taken up with DCM (about 10
mL) and evaporated under reduced pressure. The reaction mixture was purified
by flash chromatography, eluting only with DCM to give derivative 26.
Yield: 0.06 g (39%) of a yellow solid, mp 152-154◦C.
1H-NMR (DMSO, 400 MHz, figure 5.18 – 5.19) δ 2.84 (s, 3H), 3.14 (d, J = 5.0 Hz,
2H), 4.55 (pt, 1H), 6.96 (dt, J = 7.2 and 0.8 Hz, 1H), 7.01 – 7.06 (m, 2H), 7.30 (d, J =
8.0 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H), 10,33 (s, 1H), 10.88 (s, 1H).
3.2.6 5-(5-Fluoro-1H-indol-3-ylmethyl)-3-methyl-
2-thiohydantoin (29)
Methylisothiocyanate (0.041 g, 0.56 mmol) and triethylamine (0.15 mL, 1.1 mmol)
were added to a solution of 5-Fluoro-tryptophan methyl ester 28 (0.12 g, 0.51
mmol) in dry DCM (15 mL) under argon. The resulting mixture was stirred at
room temperature for 3 h under argon. It was taken up with DCM (about 10 mL)
and evaporated under reduced pressure. The reaction mixture was purified by
flash chromatography, by eluting only with DCM to give derivative 29.
Yield: 0.052 g (37%) of a yellow solid, mp 140-141◦C.
1H-NMR (DMSO, 400 MHz, figure 5.20 – 5.21) δ 2.82 (s, 3H), 3.11 (d, J = 3.8 Hz,
2H), 4.54 (t, J = 4.8 Hz, 1H), 6.87 (dt, J = 9.15 and 2.4 Hz, 1H), 7.12 (d, J = 2.3 Hz,
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1H), 7.25 – 7.30 (m, 2H), 10,31 (s, 1H), 10.98 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.22 – 5.23) δ 28.27, 29.04, 62.10, 105.52,
105.75, 110.01, 110.06, 111.39, 111.65, 114.60, 114.69, 128.67, 129.94, 130.04, 134.92,
158.06, 160.35, 177.01, 185.24.
3.2.7 5-(1-N-Methyl-1H-Indol-3-ylmethyl)-3-methyl-
2-thiohydantoin (32)
Methylisothiocyanate (0.02 g, 0.24 mmol) and triethylamine (0.04 mL, 1.2 mmol)
were added to a solution of 1-N-Methyl-tryptophan methyl ester (31) (0.05 g, 0.22
mmol) in dry DCM (5 mL) under argon. The resulting mixture was stirred at
room temperature for 2 h. It was taken up with DCM (about 10 mL) and evapo-
rated under reduced pressure. The reaction mixture was purified by flash chro-
matography, by eluting with DCM / EtOAc (from 3 up to 30% of EtOAc) to give
derivative 32.
Yield: 0.044 g (73%) of a yellow solid, mp 160-162◦C.
1H-NMR (CD3OD, 400 MHz, figure 5.24 – 5.25) δ 2.94 (pt, J = 12.47), 3.22 (pd, 3H),
3.50 (pt, J = 14.64 Hz), 3.77 (ps, 3H), 4.34 (pd, 1H), 6.95 (pd, 1H), 7.00 (s, 1H), 7.15
(pdt, 1H), 7.24 – 7.34 (m, 2H), 7.57 (pd).
13C-NMR (CD3OD, 100.6 MHz, figure 5.26 – 5.27) δ 27.46, 27.78, 32.77, 60.17,
107.68, 109.62, 118.40, 119.64, 122.27, 126.97, 127.70, 137.17, 173.54, 184.01.
3.2.8 Tryptophan methyl amide (33)
Tryptophan methyl ester hydrochloride (1 g, 3.93 mmol) was dissolved in methy-
lamine (2M) in methanol (19.7 mL, 39.3 mmol) under argon. The resulting mix-
ture was left stirring at room temperature for 48h. The remaining methylamine
was removed with argon. The reaction mixture was taken up with methanol
(about 10 mL) and evaporated under reduced pressure to give 33.
Yield: 0.84 g (98%) of a bright brown sticky paste.
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1H-NMR (DMSO, 200 MHz, figure 5.28 - 5.30) δ 2.57 (d, J = 4.7, 3H), 2.75 (pd, 1H),
3.04 (pd, 1H), 3.17 (s, 1H), 3.40 (pd, 1H) 6.92 – 7.14 (m, 3H), 7.33 (pd, J = 6.9, 1H),
7.54 (pd, J = 8.0, 1H), 7.79 (d, J = 4.5, 1H), 10.83 (s, 1H).
3.2.9 5-(1H-Indol-3-ylmethyl)-3-methyl-hydantoin (34)
Anhydrous DCM (3 mL) and triethylamine (0.32 mL, 2.48 mmol) were added to
a flask containing crude 33 (0.18 g, 0.83 mmol) under argon. The resulting mix-
ture was stirred until the temperature internally reached -10◦C (ice + salt). It was
treated portionwise with triphosgene (0.074 g, 0.25 mmol) so that the tempera-
ture did not augmented more than -7◦C. After stirring at -10◦C for 30 min, the
reaction mixture was allowed to warm to room temperature. A 0.5 M solution
of sodium carbonate was added (= quenching).The aqueous layer was washed
with DCM (10 mL x 3). The combined organic layers were dried over anhydrous
sodium sulphate, filtrated and evaporated to dryness. The residue was purified
by flash chromatography, by eluting with DCM/ MeOH (0 – 1%) to give 34.
Yield: 0.021 g (10%) of a bright yellow solid, mp 182-183◦C.
1H-NMR (DMSO, 400 MHz, figure 5.31 – 5.32) δ 2.63 (s, 3H), 3.07 (pd, 2H), 4.33
(s, 1H), 6.95 – 7.09 (m, 3H), 7.30 (d, J = 8.0, 1H), 7.51 (d, J = 7.8, 1H), 8.14 (s, 1H),
10.86 (s, 1H).
13C-NMR (DMSO, 100.6 MHz, figure 5.33 – 5.34) δ 26.27, 29.21, 59.61, 110.44,
113.72, 120.75, 120.88, 123.31, 126.48, 129.81, 138.36, 159.39, 176.63.
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Figure 5.1: 5-(1H-Indol-3-ylmethyl)-3-propyl-2-thiohydantoin (22)
Figure 5.2: compound 22
Figure 5.3: compound 22
Figure 5.4: compound 22
Figure 5.5: compound 22
Figure 5.6: 5-(1H-Indol-3-ylmethyl)-3-benzyl-2-thiohydantoin (23)
Figure 5.7: compound 23
Figure 5.8: compound 23
Figure 5.9: compound 23
Figure 5.10: 5-(1H-Indol-3-ylmethyl)-3-phenyl-2-thiohydantoin (24)
Figure 5.11: compound 24
Figure 5.12: compound 24
Figure 5.13: compound 24
Figure 5.14: (S)-5-(1H-Indol-3-ylmethyl)-3-methyl-2-thiohydantoin (25)
Figure 5.15: compound 25
Figure 5.16: compound 25
Figure 5.17: compound 25
Figure 5.18: (R)-5-(1H-Indol-3-ylmethyl)-3-methyl-2-thiohydantoin (26)
Figure 5.19: compound 26
Figure 5.20: 5-(5-Fluoro-1H-indol-3-ylmethyl)-3-methyl-2-thiohydantoin (29)
Figure 5.21: compound 29
Figure 5.22: compound 29
Figure 5.23: compound 29
Figure 5.24: 5-(1-N-Methyl-1H-Indol-3-ylmethyl)-3-methyl-2-thiohydantoin (32)
Figure 5.25: compound 32
Figure 5.26: compound 32
Figure 5.27: compound 32
Figure 5.28: Tryptophan methyl amide (33)
Figure 5.29: compound 33
Figure 5.30: compound 33
Figure 5.31: 5-(1H-Indol-3-ylmethyl)-3-methyl-hydantoin (34)
Figure 5.32: compound 34
Figure 5.33: compound 34
Figure 5.34: compound 34

B List of abbrevations
1-MT 1-Methyl-tryptophan
5-HT 5-Hydroxy-tryptamine, serotonine
APC antigen presenting cells
CD3OD deuterated methanol
DC dendritic cells
DCM dichloromethane
DMSO dimethyl sulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EtOAc ethylacetate
EtOH ethanol
HPLC high performance liqid chromatography
IDO indoleamine 2,3-dioxygenase
IFN-γ interferon-γ
IL-1 interleukin-1
K1 inhibitory constante
KP kynurenine pathway
LPS lipopolysaccharide
L-trp L-tryptophan
mAU milli absorbance unit
MeOH methanol
MTH Methyl-thiohydantoin-tryptophan
NAD nicotineamide adeninedinucleotide
PDA photodiode array (detector)
SAR structure activity relationship
TDO tryptophan 2,3-dioxygenase
TLC thin layer chromatography
TNF tumour necrosis factor

C Zusammenfassung
Das immunsuppressive Enzym Indoleamine 2,3-dioxygenase, das eine Schlüssel-
funktion im Tryptophan- Metabolismus einnimmt, wird seit geraumer Zeit mit
Immuntoleranz gegenüber Tumorgewebe in Verbindung gebracht. Es wird in ei-
nigen Krebsarten überexprimiert und ist im Stande, durch lokalen Tryptophan-
Abbau und die Akkumulierung der dadurch entstandenen cytotoxischen Meta-
boliten, die Proliferation der T-Zellen zu unterbinden und somit eine Immunant-
wort zu unterdrücken. Dieser Toleranzzustand verhindert zusätzlich eine erfol-
greiche medikamentöse Therapie.
Sowohl natürliche als auch synthetische Substanzen wurden als Hemmstoffe für
das neu etablierte Zielmolekül entdeckt und entwickelt. Bisher wurden nur zwei
davon direkt am Tumorgewebe getestet: 1-Methyl-tryptophan und Methyl-thio-
hydantoin-tryptophan. Tatsächlich zeigten beide in Kombination mit Paclitaxel
eine signifikante Tumorregression.
Das Ziel der vorliegenden Arbeit war es, neue Derivate von Methyl-thiohydanto-
in-tryptophan zu synthetisieren und sie sogleich auf ihre Enzym-Wirkung zu un-
tersuchen. Die Syntheseprodukte zeigten jedoch eine geringere Inhibitionsakti-
vität am isolierten humanen IDO als ihre Muttersubstanz.
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